COMMUNIQUÉS West-GlobeNewswire

iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting
06/11/2017
iTeos Therapeutics to Present New Data at Upcoming 2017 SITC Annual Meeting Presentations to highlight new preclinical results for A 2A antagonist and TIGIT antibody programs Gosselies, Belgium - November 6, 2017 - [...]
Amer Sports Corporation: Managers' transactions
06/11/2017
Amer Sports Corporation MANAGERS' TRANSACTIONS November 6, 2017 at 2:00 p.m. Amer Sports Corporation: Managers' transactions Person subject to the notification requirement Name: Sälzer, Bruno Position: Member of the [...]
PCI Biotech to present at BIO-Europe 2017
06/11/2017
Oslo, Norway, November 6, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at BIO-Europe 2017 [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
06/11/2017
FIT Biotech Oy Company release November 6, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Orphazyme publishes offering circular and the indicative offer price range for its IPO
06/11/2017
Company announcement Orphazyme A/S No. 2/2017 Ole Maaløes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 6 November 2017 NOT FOR RELEASE OR DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART [...]
Silmäasema Oyj: Silmäasema opens new eye clinic in the centre of Oulu
06/11/2017
Press release | Silmäasema 6 November 2017 Silmäasema opens new eye clinic in the centre of Oulu Silmäasema expands its operations in Finland and opens its fourteenth eye clinic in the centre of Oulu in February 2018. [...]
Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years
06/11/2017
For the first time for any biologic, data show almost 80 percent of ankylosing spondylitis (AS) patients on Cosentyx ® have no radiographic progression of the spine at 4 years[1] These new data also confirm sustained [...]
Novartis reaches another regulatory milestone for CTL019 (tisagenlecleucel) with submission of its MAA* to EMA for children, young adults with r/r B-cell ALL and adult patients with r/r DLBCL
06/11/2017
Application follows sBLA submission to the FDA for r/r DLBCL which marked second US application for first-ever FDA approved CAR-T therapy Building on the US r/r B-cell ALL experience, Novartis is working closely with [...]
Medtronic Receives CE Mark for the World's Smallest Fully Implantable Spinal Cord Stimulator and Announces European Launch of the Intellis Platform
06/11/2017
New Neurostimulation System Is a Non-Opioid Alternative for Chronic Pain and Offers Personalized Pain Relief and Advanced Activity Tracking DUBLIN - November 6, 2017 - Medtronic plc (NYSE:MDT) today announced that it [...]
VALNEVA Annonce sa Participation aux Conférences "Healthcare" 2017 de Jefferies et Stifel
06/11/2017
Valneva Annonce sa Participation aux Conférences "Healthcare" 2017 de Jefferies et Stifel Lyon (France), 6 novembre 2017 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie dédiée au développement, à la [...]
TiGenix announces partial conversion of bonds
06/11/2017
PRESS RELEASE TiGenix announces partial conversion of bonds Leuven (BELGIUM) - November 6, 2017, 7:00h CET - TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting [...]
TiGenix annonce une conversion partielle d'obligations
06/11/2017
COMMUNIQUÉ DE PRESSE TiGenix annonce une conversion partielle d'obligations Louvain (BELGIQUE) - le 6 novembre 2017, 7:00h CET - TiGenix NV (Euronext Brussels et NASDAQ : TIG), société biopharmaceutique de pointe axée [...]
VALNEVA to Present at Jefferies and Stifel 2017 Healthcare Conferences
06/11/2017
Valneva to Present at Jefferies and Stifel 2017 Healthcare Conferences Lyon (France), November 06, 2017 - Valneva SE ("Valneva" or "the Company"), a leading commercial stage biotech company focused on developing [...]
Consistent safety findings and durable activity with filgotinib treatment of rheumatoid arthritis patients up to week 84 in DARWIN 3 study
05/11/2017
Galapagos presents data from DARWIN 3, other filgotinib studies and Galapagos' GLPG1972 at American College of Rheumatology Meeting 2017 Mechelen, Belgium; 5 November 2017; 3 PM CET - Galapagos NV (Euronext & NASDAQ [...]
XBiotech's MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions
03/11/2017
Presentation to Discuss Novel Findings on MABp1 in the Prevention of Coronary Thrombosis AUSTIN, Texas, Nov. 03, 2017 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that research involving MABp1, the [...]
Shire plc : Director/PDMR Shareholding
03/11/2017
Director/PDMR Shareholding November 3, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial [...]
Targovax ASA: Exercise of employee share options and restricted stock units in Targovax ASA
03/11/2017
Reference is made to Targovax ASA's (the "Company") stock exchange notice of 27 October 2017 relating to the board of director's resolutions to increase the share capital in connection with exercise of employee options [...]
NICOX : Suite à l'approbation de VYZULTA, état des activités, des programmes de développement de son portefeuille de produits et point financier
03/11/2017
Communiqué de presse Nicox : suite à l'approbation de VYZULTA TM , état des activités, des programmes de développement de son portefeuille de produits et point financier VYZULTA TM (solution ophtalmique de [...]
Nicox Highlights VYZULTATM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives
03/11/2017
Press Release Nicox Highlights VYZULTA TM approval, Latest Corporate and Financial Developments, and Upcoming Pipeline Initiatives ................................... VYZULTA TM (latanoprostene bunod ophthalmic solution [...]

Pages